The IPSS-M is the newest MDS prognosis calculator that combines genomic profiling with hematologic and cytogenetic parameters, improving the risk stratification of patients with MDS. This is a valuable tool for clinical decision-making, offering the prospect of tailoring diagnosis and therapeutic interventions to each patient’s molecular profile.

Who is the MDS Foundation? We are a global non-profit advocacy organization building critical awareness of Myelodysplastic Syndromes (MDS) - a rare, often undetected blood cancer. The MDS Foundation has supported patients and their families as well as healthcare providers in the fields of MDS, AML and other related cancers for over 30 years.

2023年12月13日 · 2023 MDS Symposium MDS Regional Symposium MDS Centers of Excellence Professional Learning Center You and MDS VJHemOnc Webinars Menu 2 Material Order Form touchONCOLOGY and touchHAEMATOLOGY IPSS-R Calculator View Events Young Investigator Grants MDS Professional Working Groups

Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. MDS is often referred to as a "bone marrow failure disorder". MDS is primarily a disease of the elderly (most patients are older than age 65), but MDS can affect younger patients as well.

2025年2月25日 · MDS Patient & Family Report This new initiative of the MDS Foundation is devoted to patients, family members, and other non-professional interested people. In each episode, experts in the field will discuss novel information on MDS, such as new diagnostic techniques, new therapies etc.

The MDS Foundation, Inc.'s Young Investigator Grant provides an investigator, early in their career, the opportunity to initiate, continue or complete a project that focuses on either basic or clinical management into the causation, epidemiology, molecular biology, cytogenetics, morphology, prognosis and treatment of the Myelodysplastic Syndromes.

Who is the MDS Foundation? We are a global non-profit advocacy organization building critical awareness of Myelodysplastic Syndromes (MDS) - a rare, often undetected blood cancer. The MDS Foundation has supported patients and their families as well as healthcare providers in the fields of MDS, AML and other related cancers for over 30 years.

How Recent Developments Are Changing MDS Care Since 2020, there has been an increase in the pace of innovation, with several new MOAs established or emerging in LR- or HR-MDS1-5 + Newer MDS classifications and prognostic tools 1. Platzbecker U et al. N Eng J Med. 2020;382:140-151. 2. Garcia-Manero G et al. Blood. 2020;136:674-683. 3. Garcia ...

第1章では、骨髄異形成症候群（mds）と関連するその他の骨髄疾患に関 し、mdsを発症した際に骨髄内で何が起きるかについて現在分かっているこ と、mdsの診断方法、ご自身のmdsのリスクレベルが高いか低いかを判断する方 法を含む、一般的な情報を提供し ...

MDSF partners with SparkCures to offer personalized MDS clinical trial screening and navigation, empowering patients and caregivers with tailored options.